Dopaminergic neuronal survival-promoting factors and uses thereof
View Patent ↗In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity.
1. A substantially purified polypeptide consisting of the sequence of SEQ ID NO: 2, 11, 12, or 13.
2. The substantially purified polypeptide of claim 1 , wherein said polypeptide consists of the sequence of SEQ ID NO: 2.
3. A pharmaceutical composition comprising: (i) a substantially purified polypeptide comprising the sequence of SEQ ID NO: 2; (ii) a pharmaceutically acceptable carrier; and (iii) a neural cell.
4. The pharmaceutical composition of claim 3 , wherein said polypeptide consists essentially of the sequence of SEQ ID NO: 2.
5. A pharmaceutical composition comprising: a substantially purified polypeptide consisting of the sequence of SEQ ID NO: 2, 11, 12, or 13.
6. The pharmaceutical composition of claim 3 , wherein said neural cell is a neuron, a neural stem cell, or a neuronal precursor cell.
7. The pharmaceutical composition of claim 5 , wherein said polypeptide consists of the sequence of SEQ ID NO: 2.
8. The pharmaceutical composition of claim 5 , further comprising a pharmaceutically acceptable carrier.
9. The pharmaceutical composition of claim 5 , further comprising a neural cell.
10. The pharmaceutical composition of claim 9 , wherein said neural cell is a neuron, a neural stem cell, or a neuronal precursor cell.